news
Global clinical trials market to value $77 billion by 2026
Market analysts suggest COVID-19 and the rising prevalence of chronic disease will both contribute to growth in the global clinical trials market.
List view / Grid view
Parkinson's disease
article
Why it’s high time for psychedelic drug development
Here, Dr Matthew McMurray and Dr J Andrew Jones of Miami University explain why psychedelic drugs are attracting R&D as potential treatments for neuropsychiatric and degenerative disorders and how their discovery of an in vivo production technique could enable further advancement.
news
Global anti-Parkinson’s drugs market to be worth over $5bn by 2023
Research suggests that despite a COVID-19 slump, the anti-Parkinson’s drugs market will recover due to rising numbers of Parkinson’s diagnoses and increasing investment in R&D.
news
Collaboration to investigate nasal drug delivery using nanoparticle technology
A new partnership aims to improve blood-brain-barrier penetration in the nasal drug delivery route for certain Parkinson's therapies.
news
Smart biomaterial drug delivery system could improve CNS injury recovery
The implanted biomaterial drug delivery system releases methylprednisolone and reduces inflammation, promoting central nervous system (CNS) repair.
article
Top 10 biopharma workplaces in the US
A Fortune report reveals the best 10 places to work in the US biopharmaceutical industry.
news
Stem cells used to replace neurons in patient with Parkinson’s disease
A team has revealed that a patient who received induced pluripotent stem cells to replace lost dopaminergic neurons has reduced symptoms of Parkinson's disease.
news
Multi-arm, multi-stage clinical trials the way forward for Parkinson’s research, says study
According to a new review, multi-arm and multi-stage clinical trials should be used to evaluate potential Parkinson's treatments.
news
Nanohybrid drug delivery vehicle could help treat Alzheimer’s
The chitosan drug delivery vehicle could be used for administering polyphenol ellagic acid (EA), a potential antioxidant treatment for Alzheimer’s and Parkinson’s.
news
Patents for NLRP3 inflammasome-inhibiting compounds granted in US and Europe
Inflazome has announced that the US and EU will grant patents to their NLRP3 inflammasome inhibiting compounds.
article
IoT could transform the pharma industry through these steps
Adopting IoT systems as a pharmaceutical company can provide many opportunities but achieving success can be difficult. James Steiner explains how to effectively integrate IoT solutions into pharma.
news
Leaked document reveals ‘unprecedented’ medicine shortages in NHS
A document from the DHSC has reportedly advised NHS doctors to ration certain medicines after outlining dozens of drugs that are in shortage, as published in a report.
news
New breakthrough can effectively deliver medications into the brain
Scientists have found a way to effectively transport medication into the brain which could lead to improved treatments for neurological and neurodegenerative diseases.
news
Clinical trial to investigate the use of CBD for Parkinson’s-related psychosis
A pioneering clinical study will assess the safety, tolerability and effectiveness of CBD in people with Parkinson's-related psychosis.
news
FDA grants Fast Track Designation to Parkinson’s therapy
PR001 has received Fast Track Designation from the regulatory body for the treatment of Parkinson’s disease.
